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Abstract
Background: Childhood uveitis is a collection of chronic rare inflammatory eye disorders which result in visual loss in
at least one eye of one fifth of affected children. Despite the introduction of novel systemic immunochemotherapies, it
remains a blinding disease.
We have undertaken a systematic review of outcome measures used in interventional trials of children with, or at risk
of uveitis, in order to investigate metric quality and heterogeneity, as possible barriers to the translation of clinical
research into improved outcomes.
Methods: Systematic review of trials registered within databases approved by the International Committee of Medical
Journal Editors (ICMJE). Eligible trials for were those which involved participants aged under 18 years with or at risk of
non-infectious uveitis. Data on date of study commencement, uveitis site, inclusion age criteria, and outcome measure
characteristics including type, dimension and quality were extracted independently by two authors. Quality was
determined using the reproducibility, validity and age-appropriateness of the metric.
Results: Of 917 identified trials, 57 were eligible for inclusion. Twenty different domains across five dimensions were used
as primary outcome measures. The structure most commonly used was multiple separate outcome measures. In a quarter
of studies, outcomes were assessed less than 3months following the intervention. Disease activity was the most
commonly assessed dimension, with only 30 studies (60%) using reproducible methodologies to assess activity. Only 2/12
(18%) studies on intermediate or posterior uveitis used reproducible activity grading schemes. Of 18 studies involving
children aged under 6 years old which used outcome measures related to visual function, only 8/18 (44%) described the
use of age-appropriate acuity assessment measures. None of the studies used a vision related quality of life metrics which
had been validated for use in childhood.
Conclusion: This review of outcome measures in childhood uveitis interventional trials has identified under-utilisation
of reproducible or child appropriate measures, and considerable heterogeneity in metric type, and structure. Clinicians
and researchers interested in improving outcomes for affected children must identify a patient and family centred core
outcome set, and work to validate both objective and patient (or proxy) reported disease age appropriate outcome
measures.
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Background
Uveitis is a descriptive term used for a group of rare inflam-
matory eye diseases which can result in structural ocular
abnormalities and visual disability. Childhood uveitis, with
an estimated incidence of 5/100,000 children per annum,
accounts for less than 5% of all uveitis cases [1–3]. Almost
one in five affected children lose vision in at least one eye
by the time they reach adulthood [4–6]. Uveitis differs in
children and adults in aetiology, natural history, manage-
ment and response to therapeutics [3]. ,Childhood uveitis is
particularly challenging due to the heterogeneity of clinical
presentation, difficulties in diagnosing affected children,
and the delicate balance between the risk of insufficient
control of inflammation with the potential negative impact
of immunosuppressive chemotherapy during critical pe-
riods of ocular and general development [7]. Although
commonly an isolated ocular disorder, uveitis can also
occur as a manifestation of a multisystem inflammatory dis-
ease [4, 7]. In terms of prevalence, the most important asso-
ciated disease is juvenile idiopathic arthritis (JIA), which is
diagnosed in almost half of all childhood uveitis [7–9]. Ra-
ther than being a diagnosis per se, JIA is itself an ‘umbrella’
term for a group of idiopathic multisystem disorders which
result in chronic inflammatory arthropathy [10].
Uveitis is classified anatomically, affecting anterior,
intermediate and / or posterior ocular structures,
through clinical assessment by an ophthalmologist using
slit lamp biomicroscopy [11]. In 2005, a multinational
collaborative group developed the Standardization of
Uveitis Nomenclature (SUN) [11], which included or-
dinal scales for disease activity quantification using this
approach (Table 1). Prior to this points several different
non-coterminous ordinal scales were in use internation-
ally.10 Although vision is the key outcome of interest for
any ocular disorder, the SUN scales were adopted as out-
come measures for disease monitoring in clinical prac-
tice, and as surrogate endpoints for the irreversible,
blinding damage caused by chronic intraocular inflam-
mation [13]. Other potential outcomes of interest for
childhood uveitis, as identified through consensus work
by the Multinational Interdisciplinary Working Group
for Uveitis in Childhood (MIGWUC) [12], include the
incidence of sight threatening structural ocular compli-
cations, and the disease related impact on the child’s vis-
ual and global function, and on quality of life. As yet,
there is no uveitis specific quality of life instrument vali-
dated for use in children, and two generic instruments
(the Child Health Assessment and the Child Health
Questionnaires) are erroneously described by MIGWUC
as quality of life metrics rather than functional assess-
ments (Table 1) [12].
The advent of systemic immunomodulators has im-
proved the outlook for some affected children [13]. Des-
pite these advances, paediatric uveitis remains a blinding
disease [7]. One potential obstacle to improving out-
comes for affected children is the quality and heterogen-
eity of disease outcome measures used in studies which
assess the effectiveness of new interventions, and hetero-
geneity of utilised measures [14]. Interventional trials
are “only as credible as their outcomes” [15], and the se-
lection of patient-oriented outcomes is key to the assess-
ment of the efficacy of one intervention over another.
Once outcome domains are identified as meaningful and
appropriate, the measure used to quantify or qualify the
outcome must be able to reliably and reproducibly cap-
ture a significant change in disease or health status. Out-
come measure heterogeneity is a feature of both uveitis
research [14] and paediatric interventional research more
broadly [16, 17] and has considerable negative impact on
Table 1 Standardised Uveitis Nomenclature (SUN) Disease
activity grading schemes and Multinational Interdisciplinary
Working Group for Uveitis in Childhood (MIGWUC) outcome
parameters [11, 12]
SUN Grades (2005)
Anterior chamber cells Non-linear ordinal scale: 0 (no cells in
examined field), 0.5+ (1–5 cells), 1+ (6–15),
2+ (16–25), 3+ (26–50), 4+ (> 50 cells in
examined field)
Anterior chamber flare Non-linear ordinal scale from 0 (no
clouding of view of anterior structures) to
4+ (intense fibrin deposition in anterior
chamber)
Vitreous haze Non-linear ordinal scale from 0 (no
clouding of view through vitreous) to 4
(unable to see through vitreous gel)
MIGWUC outcome domains (2012)
Grade of activity in
anterior chamber
Slit lamp exam (subjective measure of cells
and flare) and laser photometry (objective
measure of flare), and number of visits with
active uveitis
Visual acuity Appropriate for age at testing
Development of
structural complications
Slit lamp examination for anterior structural
complications
Presence of high eye pressure or glaucoma
(diagnostic protocol not clear)
Slit lamp examination or imaging for
posterior structural complications
Quality of life Child Health Assessment Questionnairea; Child
Health Questionnairea
Pediatric Quality of life Inventory; Uveitis-
specific quality of life instrumentb
Overall uveitis related
disability
Visual analog scale scoring undertaken by
child, family, ophthalmologist or
rheumatologist
Social outcome School absence
Anti-inflammatory
medication
Reduction in corticosteroid use
Surgery Yes / no
Biomarkers Research tools
aCHAQ and CHQ are functional assessments rather than quality of life metrics
bAs yet, there is no validated instrument
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translational research [18, 19], by acting as a barrier to the
synthesis and meta-analysis needed for the generation of
an evidence base to support clinical practice.
The International Committee of Medical Journal Edi-
tors (ICMJE) has developed a system of endorsement for
clinical trial databases which meet certain quality re-
quirements. In order to receive ICMJE endorsement, a
trial registry must be open access; open to all prospect-
ive registrants; managed by a not-for-profit organization;
able to continuously ensure the validity of registered
data; electronically searchable; and must include the
minimum 20-item trial registration dataset before enrol-
ment of the first participant (full criteria available at
www.who.int/ictrp/network/trds/en/index.html). Studies
must also pre-identify primary outcome measures. These
registries form a repository of protocol data for com-
pleted and underway studies.
We have undertaken a systematic review of outcome
measures used in interventional trials of children with,
or at risk of uveitis, in order to investigate metric
quality and heterogeneity.
Main text
Methods
Identification of clinical trial registries
All clinical trial databases that were registered with, and
approved by, the ICMJE as of 10th March 2017 were
identified [http://www.icmje.org/recommendations/
browse/publishing-and-editorial-issues/clinical-trial-
registration.html]. All identified national registries were
searched and all registries were included regardless of
language. (Additional file 1).
Review inclusion criteria
Trials eligible for inclusion were those which involved
participants aged under 18 years with uveitis, or identi-
fied as at risk of uveitis due to juvenile idiopathic arth-
ritis, studies with an interventional methodology, and
with outcome measures which related to uveitis (visual
acuity, visual function, disease activity, ocular sequelae
of uveitis, or vision related quality of life measures).
Studies also had to meet the ICMJE criteria for inclusion
(Additional file 1).
Selection of trials for review
Electronic searches of the trial databases were under-
taken using the terms ‘uveitis’ and again using ‘juvenile
idiopathic arthritis’ (Additional file 1). Terms were en-
tered either free text or through key word selection, as
appropriate. Screening of identified trials was under-
taken independently by two investigators (ALS, RB).
Where no consensus was reached disagreements were
resolved by the senior author (AKD).
Data extraction
Data were independently extracted from registered pro-
tocols by two authors (ALS, RB), and comprised uveitis
site (anterior, intermediate, posterior, panuveitis or
mixed), study inclusion age criteria, date of trial registra-
tion and study commencement, trial status (active, com-
pleted, results available), the time from intervention at
which outcome was assessed, and whether the uveitis re-
lated outcome was a primary or secondary outcome
measure for the study. Data items collected on the char-
acteristics of the primary outcome measures were out-
come structure, type, and dimension.
Where trial methodology details were unavailable via
the register entry, further information was sought
through email contact with the principal investigators
for the study. Second emails were sent 4 weeks later, in
cases of non-response, with a request for further infor-
mation. A supplemental search of the literature (Add-
itional file 1) was undertaken in order to identify eligible
trials, and to identify any methodology details unavail-
able in the registered protocols.
Analyses
The domain examined within each dimension and quality
of the outcome measure was categorised using the panel
agreed by the Multinational Interdisciplinary Working
Group for Uveitis in Childhood in 2012 (Table 1) [12]. Vis-
ual function metrics were categorised as acuity or other
function, and determined to be of good quality if the assess-
ment methodology was age appropriate and validated for
use. Within the dimension of disease activity, the domain
(ie the specific study variable collected for the outcome
measure) was described. For the purpose of this review, the
metric was determined to be of good quality if reprodu-
cible. Reproducibility was defined using the guidance within
the MIGWUC consensus panel and SUN guidance. Macu-
lar oedema was classified as a marker of disease activity.
Structural or functional sequelae of inflammation were de-
fined as a diagnosis of cataract, glaucoma, band keratopa-
thy, hypotony or epiretinal membrane. As no validated
objective metric exists for these outcomes, measures
dependent on these events were determined to be of good
quality if a reproducible measure of clinical pathology was
used (eg a published grading scale used to determine sever-
ity of cataract) [20]. Patient reported metrics were deter-
mined to be of good quality for the purposes of this study if
they were validated for use within the target study popula-
tion, for example the Children and Young Person Vision
Related Quality of Life instrument (CYP_VQol) [21], or the
Child Health Assessment Questionnaire (CHAQ) [22].
We also performed subgroup analyses of registered
interventional trials and outcome measures used by (a)
date of registration (before versus after 2005, publication
of the Standardisation of Uveitis Nomenclature guidance
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[11], and 2012, the publication date of the Multinational
Interdisciplinary Working Group for Uveitis in Child-
hood’s Proposed Outcome Measures for Prospective
Clinical Trials [12]) and by (b) publication status (results
published within peer reviewed literature versus not
published) using non parametrical tests (χ2, Mann Whit-
ney U, Poisson). 95% confidence intervals are reported
where appropriate. Statistical analyses were performed
using StataSE 15 (Stata Corp, Chicago Illinois).
Results
Identification of interventional trials relevant to paediatric
uveitis
At the time of the database search (10th March 2017),
16 ICMJE endorsed registries were identified, consisting
of four international and 12 national registries (Table 2).
Searching of these registries identified 917 trials: 249 tri-
als related to childhood uveitis, 649 related to juvenile
idiopathic arthritis (JIA), and 34 related to uveitis which
were identified through the German and Indian Clinical
Trials Register, the only registries for which it was not
possible to limit the search to trials involving children.
Following removal of duplicate studies, 367 were
screened for eligibility, of which 296 were ineligible. Of
the 290 studied which were ineligible through the absence
of a uveitis related outcome measure (Fig. 1), 184 studies
involved investigations of children with JIA. We identified
57 eligible interventional studies involving participants
aged under 18 years old. Of these trials, 56 involved a
pharmacological agent, and seven of the 56 involved intra-
ocular delivery of the agent. The remaining 6 excluded
studies were ineligible due to non-involvement of children
aged under 18 years.
Characteristics of included trials
We identified 31 studies which involved participants with
a broad diagnosis of non-infectious uveitis, whilst the
remaining studies had specific populations, comprising
Juvenile Idiopathic Arthritis (n = 16 studies), anterior
uveitis secondary to cataract surgery (n = 4), Behcets (n =
4) and Chronic Infantile Neurological, Cutaneous and Ar-
ticular (CINCA) / Muckle Wells syndrome (n = 1). One
study involved children with an infectious cause for their
uveitis (Toxoplasmosis chorioretinitis). Where uveitis site
was specified (33/57 studies, 58%), the most common site
of inflammation was anterior disease with or without
intermediate involvement (27/57, 47%). Twenty-four of
the 57 studies (42%) included children with uveitis of any
anatomical category. Inclusion age ranged from 0 to 18
years. Almost 50% (29/57) of the studies excluded children
aged under 6 years old (Fig. 2), but all but one study in-
volving children with JIA included this age group.
Date of study commencement ranged from 1990 to
2016. During the 10 years prior to 2005, the publication
data of the SUN consensus guidelines on uveitis classi-
fication, there were 10 new eligible studies. During the
10 years following 2005, 35 new studies started, a statis-
tically significant increased event rate (increased rate
ratio 3.5, 95% CI 1.7–7.9, p < 0.001, Fig. 3). There was
no significant increase in study commencement rate
following publication of the Multinational Interdiscip-
linary Working Group for Uveitis in Childhood’s Pro-
posed Outcome Measures for Prospective Clinical
Trials in 2012 [12].
Table 2 Data extracted from eligible trial protocols
Primary outcome
characteristic
Details
Outcome structure Single, composite or multiple separate single
measures
Outcome type Safety, efficacy or both
Dimension Visual function
Disease activity
Use of anti-inflammatory medication
Structural or functional sequelae of
inflammation
Vision related quality of life
Other patient reported outcome measure
Fig. 1 Flow chart depicting the process of identification, screening,
and inclusion of uveitis clinical trials for this systematic review
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Fig. 2 Inclusion age range and disease site for included studies
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Outcome measure structure and type
In 15 of the studies, primary outcomes measures were not
related to uveitis outcomes (disease activity, ocular com-
plications, visual function, or vision related quality of life).
For the remaining 42 studies, all primary outcomes in-
volved measures of therapeutic efficacy, with a third (16/
42) using a single efficacy variable to assess the impact of
the intervention on children with uveitis. The structure
most commonly used was multiple separate outcome
measures (Table 2). In a quarter of studies, outcomes were
assessed less than 3months following the intervention.
Excluding studies of post-operative uveitis, for which the
median time to outcome was 3 weeks, the median time to
outcome measure was 1 year (interquartile range 0.2–2
years, total range 0.01–8 years).
We identified the use of 20 different domains across 5
dimensions to determine outcome (Table 3). Disease ac-
tivity was the most commonly assessed dimension
(Table 3), used to assess outcome in 50 of the 57 studies.
The domains examined for anterior uveitis were cell count
and flare; for intermediate uveitis were vitreous cell count
and haze; and for posterior uveitis were new onset of le-
sions, and changes on fluorescein dye angiography of pos-
terior ocular circulation. For all sites of uveitis, activity
was also assessed using the presence of macular oedema
and the use of oral or topical corticosteroids.
Outcome measure quality
We identified 30 studies (60%) which used reproducible
methodologies to assess disease activity. The SUN grading
schemes were used in 11/27 studies undertaken after 2006
where the intervention was specifically for anterior disease
with or without intermediate involvement. Objective assess-
ment of the anterior chamber was used in 2 studies (both
of which used a laser flare photometry machine [23] to as-
sess light scatter caused by the presence of inflammatory
cells). Only 2/12 (18%) studies involving participants with
intermediate or posterior disease used SUN grading
schemes. The most commonly used outcome was vitreous
cell count, (Table 4) which is not part of the SUN grading
scheme [11]. Macular oedema was used as a measure of ac-
tivity in 21/57 (37%) studies, with objective assessment
(through optical coherence tomography retinal imaging) in
19 studies. Disease activity was assessed using a domain
Fig. 3 Year of study commencement for included studies. With
vertical reference lines indicating publication dates of Standardised
Uveitis Nomenclature (SUN) [11] guidelines, and the Multinational
Interdisciplinary Working Group for Uveitis in Childhood (MIGWUC)
[12] proposed outcome measures
Table 3 Distribution of trial registrations
Registry Uveitisa Childhood
uveitisa
JIAa
National registries
Australian New Zealand Clinical Trials
Registry (ANZCTR)
http://www.anzctr.org.au/
20 2 18
Brazilian Clinical Trials Registry (ReBec)
http://www.ensaiosclinicos.gov.br/
0 0 1
Chinese Clinical Trial Registry (ChiCTR)
http://www.chictr.org.cn/enIndex.aspx
5 2 0
Clinical Research Information Service
(CRiS), Republic of Korea
http://cris.nih.go.kr/cris/en/use_guide/cris_
introduce.jsp
0 0 0
Clinical Trials Registry - India (CTRI)
http://ctri.nic.in/Clinicaltrials/login.php
15 -b 2
Cuban Public Registry of Clinical Trials
(RPCEC)
http://registroclinico.sld.cu/en/home
4 0 1
German Clinical Trials Register (DRKS)
https://www.drks.de/drks_web/
19 -b 54
Iranian Registry of Clinical Trials (IRCT)
http://www.irct.ir/
33 1 0
Japan Primary Registries Network (JPRN)
https://rctportal.niph.go.jp/en/link
91 6 16
Thai Clinical Trials Registry (TCTR)
http://www.clinicaltrials.in.th/
2 0 0
The Netherlands National Trial Register
(NTR)
http://www.trialregister.nl/trialreg/index.asp
4 0 5
Sri Lanka Clinical Trials Registry (SLCTR)
https://slctr.lk/trials
0 0 0
U.S. National Institutes of Health: USA
only
https://clinicaltrials.gov/
177 63 82
International registries
U.S. National Institutes of Health:
International
https://clinicaltrials.gov/
328 107 192
ISCTRP
http://apps.who.int/trialsearch
302 59 217
Pan African Clinical Trial Registry (PACTR)
http://www.pactr.org/
0 0 0
EU Clinical Trials Register (EU-CTR)
https://www.clinicaltrialsregister.eu/
78 9 61
Total individual studies (excluding
duplications)
271 249 649
aFigures include studies registered across multiple registries
bRegistry search programme did not enable search filtered participant age
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defined by the concurrent use of systemic or topical cor-
ticosteroid in eight studies (14%).
On subgroup analysis of the use of any reproducible as-
sessments of disease activity before and after publication of
the 2005 SUN guidance and 2012 MIGWUC guidance, al-
though there was a higher proportion of studies using repro-
ducible scales following publication of SUN guidance (23/
35, 66%, versus 3/9, 33%) this difference was not significant.
Visual function, which for all relevant studies was mea-
sured using acuity, was utilised as a primary outcome
measure for almost all studies involving posterior uveitis,
but under a third of those involving only participants with
anterior uveitis. In the 18 studies involving children aged
under 6 years old which used visual function outcome
measures, only 8/18 (44%) described the use of age-
appropriate acuity assessment measures.
The incidence of structural or functional sequelae of
inflammation were used as outcome measures in 12
studies. In 3 studies the incidence of cataract was speci-
fied as an outcome measure, and 4 studies used the de-
velopment of glaucoma as a specific outcome event. No
study described a reproducible method of assessing the
presence of structural complications, such as optic disc
imaging for glaucoma.
In all three studies in which vision related function mea-
sures were used to measure disease outcomes, investigators
used the NEI VFQ-25 tool, which was developed for use in
adults [24]. None of the five studies which assessed vision
related quality of life used metrics which were validated for
use in childhood, such as the Children and Young Person
Vision Related Quality of Life instrument [25].
Table 4 Characteristics of outcome measures in included trials
by uveitis type
Anterior
(n = 20)
Anterior &
intermediate
(n = 7)
Posterior
(n = 5)
Any
site
(n =
24)
Total
(n =
57)
Uveitis related
primary outcome
18 4 3 17 42
Safety only 0 0 0 0 0
Single efficacy 9 2 1 4 16
Multiple separate
efficacy
7 2 2 11 22
Composite
efficacy
2 0 0 2 4
Time to outcome
measure in years
(IQR)
0.04–0.5 0.4–3 1–2.5 0.5–2 0.2–2
Activity 20 8 5 18 47
ACC inactive
SUN grade
7 3 – 4 –
ACC 2 step
change SUN
grade
1 0 – 3 –
Objective
assessment AC
Flare
1 1 0 0 –
Other AC
assessment
11 4 2 1 –
Vitreous CC
zero
– 3 0 1 –
Vitreous 2 step
change SUN
grade
– 0 0 2 –
Vitreous CC
reduction
– 0 2 3 –
Objective
assessment
vitreous
– 0 0 0 –
Other vitreous
assessment
– 5 1 1 –
Macular
oedema (MO)
3 2 3 13 21
Objective
assessment
MO
2 2 3 12 19
Use of topical
steroids
1 1 1 4 7
Use of
systemic
steroids
0 2 1 4 7
Visual acuity 4 1 3 14 21
Age
appropriate
measure
0 1 1 6 8
Reproducible
assessment of
cataract
0 0 0 0 0
Table 4 Characteristics of outcome measures in included trials
by uveitis type (Continued)
Anterior
(n = 20)
Anterior &
intermediate
(n = 7)
Posterior
(n = 5)
Any
site
(n =
24)
Total
(n =
57)
Reproducible
assessment of
glaucoma
0 0 0 0 0
Reproducible
assessment of
band keratopathy
0 0 0 0 0
Vision related
function
1 0 0 2 3
Vision related
quality of life
1 0 2 0 3
Non-specific
quality of life
measure
1 0 1 1 3
Validated for use
in children
0 0 0 0 0
ACC anterior cells count, SUN Standardised Uveitis Nomenclature, AC, anterior
chamber, CC Cell count
Solebo et al. Orphanet Journal of Rare Diseases          (2019) 14:125 Page 7 of 11
Outcome measure characteristics by study completion
and dissemination status
Of the 57 studies, 27 were described as completed
and had published their findings either directly
within their registry entry (n = 3) or through a publi-
cation linked to the entry (n = 11). Contrary to
ICMJE guidance, 13/27 studies had disseminated
their findings through publications which were not
linked to their registry entry, and which were only
identified through the accompanying review of pub-
lished randomised controlled trials. Status was de-
scribed as completed but without available results for
8 studies, active or ongoing for 14 studies, and un-
known for 7 studies. One study had been terminated
due to low enrolment rates. Dimensions used in
studies which had published results were compared
to those which had not yet disseminated out-
comes (Fig. 4). In order to provide an appropriate
comparison by only including studies which had suf-
ficient time post study completion in order to dis-
seminate findings, we excluded studies with an
estimated completion date of later than January 2015.
Although, across all uveitis types, all of the three
most commonly assessed dimensions (visual acuity,
disease activity, structural sequelae of inflammation)
were all more likely to be utilised in studies which
had disseminated results, our study sample size gives
this review insufficient power to determine whether
this difference is statistically significant.
Discussion
This review of outcome measures used in interventional
trials involving children with or at risk of uveitis has iden-
tified considerable heterogeneity in metric type, structure,
and time at which outcome was assessed. This heterogen-
eity may be a reflection of the poor quality of the outcome
measures used: 40% of studies used non-reproducible
methodologies to assess disease activity outcomes, and the
outcome measures which related to dimensions such as
quality of life, structural complications, or functional se-
quelae of uveitis, were not validated for use in childhood.
Our review searched within registries of interventional
trials, rather than within the published literature, in
order to overcome the obstacle of publication bias and
the outcome reporting bias, in which ‘negative’ trials,
and ‘negative’ outcomes are not reported respectively
[26]. Consequently, studies which have not been regis-
tered on an ICMJE recognised system have not been
evaluated. As registration has, since 2005, been a pre-
requisite for publication within an ICJME journal, it is
unlikely that our approach has resulted in significant
omissions of ongoing or completed studies. Full details
of study methodology were not always available through
the ICMJE-recognised registries. Although we sought
further details through a supplementary search of the
published literature and attempted communications with
registered principal investigators for methodology de-
tails, we may be missing details which clarify the repro-
ducibility of the metrics chosen by the reported studies.
Fig. 4 Proportion of studies assessing the different outcome dimensions, by inflammation site and by study dissemination status
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The annual registration rate of trials involving children
with uveitis increased significantly after 2005, that is in
the years following the publication of the SUN guide-
lines. There are a number of possible explanations for
this: first it may be that the registration of a number of
trials in planning phase were deferred until the widely-
anticipated SUN consensus had reported; second, it may
be that the SUN consensus itself stimulated a number of
trials by providing a much needed structure, reproduci-
bility, and specificity to the measurement of disease ac-
tivity; thirdly, this could be a chance finding. We also
recognise that studies which commenced prior to 2005
and which were not registered within the ICMJE may
have been omitted from our review.
Rare disease interventional research faces the chal-
lenge of adequate study recruitment to ensure sufficient
sample sizes, exacerbated by the measurement and se-
lection biases at play in the study of complex disease
states. Additionally, small numbers and other methodo-
logical and logistical challenges constrain researchers’
ability to undertake randomised controlled trials. Repro-
ducible, precise and validated outcome metrics are key
to study feasibility, as are surrogate endpoints. Surrogate
endpoints are a particular concern in paediatric rare dis-
ease research: the developmental trajectory of children
with rare disease is often disturbed, weakening our abil-
ity to prognosticate on findings reported early in the dis-
ease course. Other obstacles to paediatric rare disease
research include the appropriateness of outcome mea-
sures at different developmental stages. Almost 50% of
all the studies excluded children aged under 6 years old,
which may be a reflection of the difficulty in capturing
outcome for young children. However, younger children
are at particular risk of disease: JIA typically presents in
children aged under 6 years, and this multisystem dis-
ease has a uveitis prevalence of 20–30% [7, 27, 28], with
young age at presentation being a risk factor for poor
outcomes in JIA associated uveitis [4, 6, 28]. Despite
uveitis being a frequent extra-articular manifestation of
JIA, we identified 184 interventional trials of children
with JIA which did not include uveitis as an outcome
measure, suggesting an importance evidence gap for re-
search on this population. This disconnect between JIA
and childhood uveitis research may be another obstacle
to the translation of research into clinical care.
The absence of robust evidence on the long term clin-
ical significance of different levels of inflammation in
uveitis, and the imprecision and insensitivity of the
current metrics of disease activity, complicate the use of
inflammation as a surrogate endpoint for visual disabil-
ity. The long duration of follow up necessary to capture
uveitic visual loss, and the irreversibility of uveitic visual
loss, make visual function a challenging end point for
interventional childhood inflammatory disease research,
and highlight the importance of developing a validated
outcome able to predict final visual function (a ‘surro-
gate endpoint’). For children with uveitis, the majority of
whom (80%) [1, 7] have chronic anterior disease, disease
activity is the most commonly measured outcome di-
mension in interventional clinical research, and is used
as a surrogate endpoint for visual disability. There is evi-
dence that chronic disease activity results in visual dis-
ability, but the dose-response relationship is unclear,
particularly for those with milder degrees of inflamma-
tion. There is also absence of clarity on the key end
point for disease activity: ie whether inactive disease, or
significant reduction in disease activity is the more ap-
propriate measure of effectiveness [4, 6]. Additionally,
the grading scales currently used to quantify activity are
subjective, semi-quantitative, non-linear, open to intra-
and interobserver variability [29], and have not been val-
idated for use in children [7]. Objective disease activity
metrics would support research on the prognostic im-
pact of disease activity, as well as providing a precise, ac-
curate and reproducible outcome measure. Laser flare
photometry, in which the scatter of light by products
within the eye is measured by a desktop instrument, has
been successfully used to quantify disease activity [23,
30], and in recent trials were used to assess the efficacy
of adalimumab in children with chronic anterior JIA as-
sociated uveitis [13, 31]. Laser flare meters provide an
objective machine-based metric of disease activity, but
have had little adoption into routine clinical practice due
to expense, perceived difficulty of use, limited use be-
yond anterior chamber assessment, and the inability of
these instruments to quantify anterior chamber cell
counts. Optical coherence tomography (OCT) photog-
raphy, a non-contact near infra-red high resolution im-
aging system, which is able to detect blood cells and
proteinaceous exudate within the intraocular spaces,
may have a future role in the quantification of disease
activity in uveitis [32–37].
In order to impact on clinical practice, interventional tri-
als must evaluate outcomes which are meaningful to pa-
tients as well as practitioners. There has been little work on
the importance of various outcome measures to children
and families with uveitis, and a paucity of validated patient
reported outcome measures (PROMs) for this group. Such
work is necessary if clinical trials are to translate into im-
provements for affected children. There is also absence of
clarity within the paediatric uveitis clinical research com-
munity on PROMs, with functional assessments (which
measure the impact of disease on the child’s ability across
different dimensions) conflated for quality of life metrics
(which enable the child to quantify the self-perceived nega-
tive impact of their disease on their life) [12].
Multiplicity of outcome measures and use of compos-
ite outcomes can dilute the ability of individual RCT
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findings to support clinical care, and outcome metric
heterogeneity is an obstacle to the synthesis or meta-
analysis of the existing literature. Inconsistency of out-
come selection also leads to clinical trials with unneces-
sarily large sample sizes, and to reporting biases [19, 38].
The Core Outcome Measures in Effectiveness Trials
(COMET) initiative, which aims to collate and stimulate
resources for the development and application of core
outcome sets for clinical research, has gained interest
and prominence since its establishment in 2011, with
sustained growth in use of COMET resources [39]. Of
the 1033 references relating to planned, ongoing and
completed work on determining ‘Core Outcome Sets’
currently collated on the COMET initiative website, 18
refer to eye or vision disorders [40].
In summary, our review reports on the paucity of re-
producible, age appropriate and patient reported out-
come measures in childhood uveitis interventional
research, and significant heterogeneity of utilised out-
come measures. Although the clinical research commu-
nity is working on COMET supported consensus based
and patient centred approaches to outcome measures in
adult uveitis [41], these advances may not translate to af-
fected children. Clinicians and researchers interested in
improving outcomes for children with uveitis must iden-
tify a patient and family centred core outcome set. This
will need the active involvement of children and families
in priority setting, and the outcome domains will need
to consider the child’s developmental stage, and the dur-
ation of follow up at which the outcome is measured.
Work will then be needed to validate these objective and
/ or patient reported outcome measures.
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